In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Warner Chilcott gets US rights to Novartis' Enablex

Executive Summary

Novartis AG has granted Warner Chilcott PLC (primarily dermatology, women's health, gastrointestinal, and muscloskeletal conditions) exclusive US marketing rights to Enablex (darifenacin) extended-release tablets for adults with symptoms of an overactive bladder, which include urge urinary incontinence, urgency, and frequency.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing-Licensing
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register